Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.

[1]  A. Skene,et al.  Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. , 2005, The New England journal of medicine.

[2]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[3]  M. Pfeffer,et al.  Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes , 2004 .

[4]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[5]  J. Staffa,et al.  Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy , 2004, Pharmacoepidemiology and drug safety.

[6]  Richard M. Moe,et al.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.

[7]  E. Topol.  Intensive statin therapy--a sea change in cardiovascular prevention. , 2004, The New England journal of medicine.

[8]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[9]  H. Silbershatz,et al.  Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. , 2003, The American journal of cardiology.

[10]  P. Thompson,et al.  Statin-associated myopathy. , 2003, JAMA.

[11]  J. Shepherd,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .

[12]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[13]  S. Grundy.  Approach to lipoprotein management in 2001 National Cholesterol Guidelines. , 2002, The American journal of cardiology.

[14]  S. Grundy,et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Circulation.

[15]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[16]  B. Davis,et al.  Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project , 2002, Circulation.

[17]  E. Braunwald,et al.  Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.

[18]  Jennie Chang,et al.  Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.

[19]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[20]  S. Grundy.  United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. , 2001, The American journal of cardiology.

[21]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[22]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[23]  D. Black,et al.  Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. , 2000, Atherosclerosis.

[24]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[25]  G. Schlüter,et al.  Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. , 1998, The American journal of cardiology.

[26]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[27]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[28]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[29]  H. Iso,et al.  Serum total cholesterol and mortality in a Japanese population. , 1994, Journal of clinical epidemiology.

[30]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[31]  D. Jacobs,et al.  Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial , 1992 .

[32]  D. Jacobs,et al.  Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1992, Archives of internal medicine.

[33]  K. Yano,et al.  Serum cholesterol and mortality among Japanese-American men. The Honolulu (Hawaii) Heart Program. , 1991, Archives of internal medicine.

[34]  A. Alberts,et al.  Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1988, The American journal of pathology.

[35]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.

[36]  Michael Miller.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[37]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .